Sign in Subscribe

real-world

A collection of 51 issues

Real-world data show fruquintinib efficacy in Japanese patients with advanced colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Real-world data show fruquintinib efficacy in Japanese patients with advanced colorectal cancer A multicentre retrospective study of 171 Japanese patients with unresectable or recurrent colorectal cancer treated with fruquintinib monotherapy evaluated real-world progression-free survival, overall survival, and safety outcomes. (ESMO Gastrointestinal Oncology) This

Electronic Health Record Intervention Improves Colonoscopy Scheduling Intervals

Skip to content The CRC Digest ▪ SCREENING Electronic Health Record Intervention Improves Colonoscopy Scheduling Intervals An academic medical center implemented an EHR-based intervention to improve adherence to guideline-recommended 5-year intervals for screening and surveillance colonoscopies, addressing the common problem of procedures being scheduled earlier than recommended. (Gastro Hep Adv) This

Half of Canadian CRC patients report nutrition status was never or inconsistently discussed during treatment

Skip to content The CRC Digest Half of Canadian CRC patients report nutrition status was never or inconsistently discussed during treatment A national survey of 243 participants found 51.2% of patients had nutritional status discussed, while 24.0% reported it was never addressed. (Current Oncology) This content is informational

Impact of the Australian National Bowel Cancer Screening Program on Stage at Diagnosis and Survival

Skip to content The CRC Digest ▪ SCREENING Impact of the Australian National Bowel Cancer Screening Program on Stage at Diagnosis and Survival A retrospective cohort study of 881 colorectal cancer episodes from 2010 to 2024 examined overall survival differences between screen-detected and non-screen-detected cancers for each stage I-III; the Australian

FIT-based screening linked to earlier colorectal cancer detection in Romania

Skip to content The CRC Digest ▪ SCREENING FIT-based screening linked to earlier colorectal cancer detection in Romania A retrospective study of 236 patients found that population-based screening using the fecal immunochemical test detected colorectal cancer at earlier stages compared to symptom-driven colonoscopy. (Cancers) This content is informational only and does

Early-onset and average-onset metastatic colorectal cancer share similar genomic landscapes

Skip to content The CRC Digest ◇ RESEARCH Early-onset and average-onset metastatic colorectal cancer share similar genomic landscapes An analysis of 1,892 patients found that major driver alterations. TP53, APC, and KRAS — occurred at comparable frequencies in metastatic colorectal cancer diagnosed before age 50 versus later, suggesting the diseases are

Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab

Skip to content The CRC Digest ▸ TREATMENT Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab A multicenter study across 19 Spanish hospitals evaluated real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer after at least two prior treatment regimens. (ESMO Gastrointestinal

Study evaluates follow-up after positive stool-based screening in rural populations

Skip to content The CRC Digest ▪ SCREENING Study evaluates follow-up after positive stool-based screening in rural populations (The American Surgeon) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC

Skip to content The CRC Digest ▸ TREATMENT Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC A U.S. healthcare payer analysis evaluated nivolumab plus ipilimumab versus pembrolizumab and chemotherapy as first-line treatment for the 4-5% of metastatic colorectal cancers that are microsatellite instability-high or mismatch repair deficient. (Advances in

Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC

Skip to content The CRC Digest Fruquintinib plus immunotherapy evaluated in MSS refractory mCRC A retrospective study of 145 patients with microsatellite-stable metastatic CRC who had progressed after at least two systemic treatment lines aimed to evaluate whether fruquintinib alone, fruquintinib plus a PD-1 inhibitor, or the combination with radiotherapy